The subject of this publication is the conclusion of agreements in accordance with Section 130a (8) SGB V on various active substances / combinations of active substances within the framework of a so-called open house procedure. See the respective lot for details.

The subject of this publication is the conclusion of agreements in accordance with Section 130a (8) SGB V on various active substances / combinations of active substances as part of a so-called open house process. Providing uniform contractual terms and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the conclusion or entry to a discount contract in accordance with Section 130a (8) SGB V for the active substances / combinations of active substances mentioned. Interested pharmaceutical companies can request the participation documents and the contract from the contact address given under l.1). The e-mail address specified under Section I: Contracting authority, point 1.3.) Communication for the purpose of unrestricted and complete fee-free access to the order documents does not exist. Information and the provision of the contract documents can be requested at the following email address: fp_open-house@nordost.aok.de. A precondition for the conclusion of a contract is that the interested pharmaceutical company has completed and signed the requested participation documents. Any pharmaceutical company that meets the participation requirements and documents this by signing the declarations and the discount contract can join the discount contract. There is no exclusivity. The accession or the conclusion of the contract can take place at any time and under the same conditions. Individual contract negotiations are not carried out. The start of the contract can only be one month in advance. The earliest contract start date is October 1st, 2020. Based on this, the contract term is a maximum of 24 months. The contract ends on 30.09.2022 at the latest, regardless of the date of the conclusion of the contract. The offer must be available when the contract begins on October 1, 2020 by August 27, 2020, but no contracts are concluded by AOK Nordost before September 7, 2020. For a later start of the contract, the submission deadline for the offers is the 5th of the previous month. (Example: start of contract November 1st, 2020; deadline for submitting the offer: October 5th, 2020). Should AOK Nordost award an exclusive contract for the active substance / active substance combination within the framework of an open procedure during the contract period, the contractual regulations concluded in the context of this publication apply. This publication is not a public contract within the meaning of the Coordination Coordination Directive 2014/24 / EU of the European Parliament and of the Council or of public procurement law. In order to ensure the greatest possible degree of transparency for the intended contracts, the publication is published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the procedure name for open procedure, are solely due to the use of this notice form and the publication platform. This does not imply any further significance, in particular submission to public procurement regulations, unless they are required for legal reasons. Since 01.09.2016, the orders placed have only been announced on the website www.aok-gesundheitpartner.de.

The subject of this publication is the conclusion of agreements in accordance with Section 130a (8) SGB V on various active substances / combinations of active substances as part of a so-called open house process. Providing uniform contractual terms and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the conclusion or entry to a discount contract in accordance with Section 130a (8) SGB V for the active substances / combinations of active substances mentioned. Interested pharmaceutical companies can request the participation documents and the contract from the contact address given under l.1). The e-mail address specified under Section I: Contracting authority, point 1.3.) Communication for the purpose of unrestricted and complete fee-free access to the order documents does not exist. Information and the provision of the contract documents can be requested at the following email address: fp_open-house@nordost.aok.de. A precondition for the conclusion of a contract is that the interested pharmaceutical company has completed and signed the requested participation documents. Any pharmaceutical company that meets the participation requirements and documents this by signing the declarations and the discount contract can join the discount contract. There is no exclusivity. The accession or the conclusion of the contract can take place at any time and under the same conditions. Individual contract negotiations are not carried out. The start of the contract can only be one month in advance. The earliest contract start date is October 1st, 2020. Based on this, the contract term is a maximum of 24 months. The contract ends on 30.09.2022 at the latest, regardless of the date of the conclusion of the contract. The offer must be available when the contract begins on October 1, 2020 by August 27, 2020, but no contracts are concluded by AOK Nordost before September 7, 2020. For a later start of the contract, the submission deadline for the offers is the 5th of the previous month. (Example: start of contract November 1st, 2020; deadline for submitting the offer: October 5th, 2020). Should AOK Nordost award an exclusive contract for the active substance / active substance combination within the framework of an open procedure during the contract period, the contractual regulations concluded in the context of this publication apply. This publication is not a public contract within the meaning of the Coordination Coordination Directive 2014/24 / EU of the European Parliament and of the Council or of public procurement law. In order to ensure the greatest possible degree of transparency for the intended contracts, the publication is published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the procedure name for open procedure, are solely due to the use of this notice form and the publication platform. This does not imply any further significance, in particular submission to public procurement regulations, unless they are required for legal reasons. Since 01.09.2016, the orders placed have only been announced on the website www.aok-gesundheitpartner.de.

The subject of this publication is the conclusion of agreements in accordance with Section 130a (8) SGB V on various active substances / combinations of active substances as part of a so-called open house process. Providing uniform contractual terms and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the conclusion or entry to a discount contract in accordance with Section 130a (8) SGB V for the active substances / combinations of active substances mentioned. Interested pharmaceutical companies can request the participation documents and the contract from the contact address given under l.1). The e-mail address specified under Section I: Contracting authority, point 1.3.) Communication for the purpose of unrestricted and complete fee-free access to the order documents does not exist. Information and the provision of the contract documents can be requested at the following email address: fp_open-house@nordost.aok.de. A precondition for the conclusion of a contract is that the interested pharmaceutical company has completed and signed the requested participation documents. Any pharmaceutical company that meets the participation requirements and documents this by signing the declarations and the discount contract can join the discount contract. There is no exclusivity. The accession or the conclusion of the contract can take place at any time and under the same conditions. Individual contract negotiations are not carried out. The start of the contract can only be one month in advance. The earliest contract start date is October 1st, 2020. Based on this, the contract term is a maximum of 24 months. The contract ends on 30.09.2022 at the latest, regardless of the date of the conclusion of the contract. The offer must be available when the contract begins on October 1, 2020 by August 27, 2020, but no contracts are concluded by AOK Nordost before September 7, 2020. For a later start of the contract, the submission deadline for the offers is the 5th of the previous month. (Example: start of contract November 1st, 2020; deadline for submitting the offer: October 5th, 2020). Should AOK Nordost award an exclusive contract for the active substance / active substance combination within the framework of an open procedure during the contract period, the contractual regulations concluded in the context of this publication apply. This publication is not a public contract within the meaning of the Coordination Coordination Directive 2014/24 / EU of the European Parliament and of the Council or of public procurement law. In order to ensure the greatest possible degree of transparency for the intended contracts, the publication is published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the procedure name for open procedure, are solely due to the use of this notice form and the publication platform. This does not imply any further significance, in particular submission to public procurement regulations, unless they are required for legal reasons. Since 01.09.2016, the orders placed have only been announced on the website www.aok-gesundheitpartner.de.

The subject of this publication is the conclusion of agreements in accordance with Section 130a (8) SGB V on various active substances / combinations of active substances as part of a so-called open house process. Providing uniform contractual terms and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the conclusion or entry to a discount contract in accordance with Section 130a (8) SGB V for the active substances / combinations of active substances mentioned. Interested pharmaceutical companies can request the participation documents and the contract from the contact address given under l.1). The e-mail address specified under Section I: Contracting authority, point 1.3.) Communication for the purpose of unrestricted and complete fee-free access to the order documents does not exist. Information and the provision of the contract documents can be requested at the following email address: fp_open-house@nordost.aok.de. A precondition for the conclusion of a contract is that the interested pharmaceutical company has completed and signed the requested participation documents. Any pharmaceutical company that meets the participation requirements and documents this by signing the declarations and the discount contract can join the discount contract. There is no exclusivity. The accession or the conclusion of the contract can take place at any time and under the same conditions. Individual contract negotiations are not carried out. The start of the contract can only be one month in advance. The earliest contract start date is October 1st, 2020. Based on this, the contract term is a maximum of 24 months. The contract ends on 30.09.2022 at the latest, regardless of the date of the conclusion of the contract. The offer must be available when the contract begins on October 1, 2020 by August 27, 2020, but no contracts are concluded by AOK Nordost before September 7, 2020. For a later start of the contract, the submission deadline for the offers is the 5th of the previous month. (Example: start of contract November 1st, 2020; deadline for submitting the offer: October 5th, 2020). Should AOK Nordost award an exclusive contract for the active substance / active substance combination within the framework of an open procedure during the contract period, the contractual regulations concluded in the context of this publication apply. This publication is not a public contract within the meaning of the Coordination Coordination Directive 2014/24 / EU of the European Parliament and of the Council or of public procurement law. In order to ensure the greatest possible degree of transparency for the intended contracts, the publication is published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the procedure name for open procedure, are solely due to the use of this notice form and the publication platform. This does not imply any further significance, in particular submission to public procurement regulations, unless they are required for legal reasons. Since 01.09.2016, the orders placed have only been announced on the website www.aok-gesundheitpartner.de.

The subject of this publication is the conclusion of agreements in accordance with Section 130a (8) SGB V on various active substances / combinations of active substances as part of a so-called open house process. Providing uniform contractual terms and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the conclusion or entry to a discount contract in accordance with Section 130a (8) SGB V for the active substances / combinations of active substances mentioned. Interested pharmaceutical companies can request the participation documents and the contract from the contact address given under l.1). The e-mail address specified under Section I: Contracting authority, point 1.3.) Communication for the purpose of unrestricted and complete fee-free access to the order documents does not exist. Information and the provision of the contract documents can be requested at the following email address: fp_open-house@nordost.aok.de. A precondition for the conclusion of a contract is that the interested pharmaceutical company has completed and signed the requested participation documents. Any pharmaceutical company that meets the participation requirements and documents this by signing the declarations and the discount contract can join the discount contract. There is no exclusivity. The accession or the conclusion of the contract can take place at any time and under the same conditions. Individual contract negotiations are not carried out. The start of the contract can only be one month in advance. The earliest contract start date is October 1st, 2020. Based on this, the contract term is a maximum of 24 months. The contract ends on 30.09.2022 at the latest, regardless of the date of the conclusion of the contract. The offer must be available when the contract begins on October 1, 2020 by August 27, 2020, but no contracts are concluded by AOK Nordost before September 7, 2020. For a later start of the contract, the submission deadline for the offers is the 5th of the previous month. (Example: start of contract November 1st, 2020; deadline for submitting the offer: October 5th, 2020). Should AOK Nordost award an exclusive contract for the active substance / active substance combination within the framework of an open procedure during the contract period, the contractual regulations concluded in the context of this publication apply. This publication is not a public contract within the meaning of the Coordination Coordination Directive 2014/24 / EU of the European Parliament and of the Council or of public procurement law. In order to ensure the greatest possible degree of transparency for the intended contracts, the publication is published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the procedure name for open procedure, are solely due to the use of this notice form and the publication platform. This does not imply any further significance, in particular submission to public procurement regulations, unless they are required for legal reasons. Since 01.09.2016, the orders placed have only been announced on the website www.aok-gesundheitpartner.de.

The subject of this publication is the conclusion of agreements in accordance with Section 130a (8) SGB V on various active substances / combinations of active substances as part of a so-called open house process. Providing uniform contractual terms and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the conclusion or entry to a discount contract in accordance with Section 130a (8) SGB V for the active substances / combinations of active substances mentioned. Interested pharmaceutical companies can request the participation documents and the contract from the contact address given under l.1). The e-mail address specified under Section I: Contracting authority, point 1.3.) Communication for the purpose of unrestricted and complete fee-free access to the order documents does not exist. Information and the provision of the contract documents can be requested at the following email address: fp_open-house@nordost.aok.de. A precondition for the conclusion of a contract is that the interested pharmaceutical company has completed and signed the requested participation documents. Any pharmaceutical company that meets the participation requirements and documents this by signing the declarations and the discount contract can join the discount contract. There is no exclusivity. The accession or the conclusion of the contract can take place at any time and under the same conditions. Individual contract negotiations are not carried out. The start of the contract can only be one month in advance. The earliest contract start date is October 1st, 2020. Based on this, the contract term is a maximum of 24 months. The contract ends on 30.09.2022 at the latest, regardless of the date of the conclusion of the contract. The offer must be available when the contract begins on October 1, 2020 by August 27, 2020, but no contracts are concluded by AOK Nordost before September 7, 2020. For a later start of the contract, the submission deadline for the offers is the 5th of the previous month. (Example: start of contract November 1st, 2020; deadline for submitting the offer: October 5th, 2020). Should AOK Nordost award an exclusive contract for the active substance / active substance combination within the framework of an open procedure during the contract period, the contractual regulations concluded in the context of this publication apply. This publication is not a public contract within the meaning of the Coordination Coordination Directive 2014/24 / EU of the European Parliament and of the Council or of public procurement law. In order to ensure the greatest possible degree of transparency for the intended contracts, the publication is published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the procedure name for open procedure, are solely due to the use of this notice form and the publication platform. This does not imply any further significance, in particular submission to public procurement regulations, unless they are required for legal reasons. Since 01.09.2016, the orders placed have only been announced on the website www.aok-gesundheitpartner.de.

The subject of this publication is the conclusion of agreements in accordance with Section 130a (8) SGB V on various active substances / combinations of active substances as part of a so-called open house process. Providing uniform contractual terms and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the conclusion or entry to a discount contract in accordance with Section 130a (8) SGB V for the active substances / combinations of active substances mentioned. Interested pharmaceutical companies can request the participation documents and the contract from the contact address given under l.1). The e-mail address specified under Section I: Contracting authority, point 1.3.) Communication for the purpose of unrestricted and complete fee-free access to the order documents does not exist. Information and the provision of the contract documents can be requested at the following email address: fp_open-house@nordost.aok.de. A precondition for the conclusion of a contract is that the interested pharmaceutical company has completed and signed the requested participation documents. Any pharmaceutical company that meets the participation requirements and documents this by signing the declarations and the discount contract can join the discount contract. There is no exclusivity. The accession or the conclusion of the contract can take place at any time and under the same conditions. Individual contract negotiations are not carried out. The start of the contract can only be one month in advance. The earliest contract start date is October 1st, 2020. Based on this, the contract term is a maximum of 24 months. The contract ends on 30.09.2022 at the latest, regardless of the date of the conclusion of the contract. The offer must be available when the contract begins on October 1, 2020 by August 27, 2020, but no contracts are concluded by AOK Nordost before September 7, 2020. For a later start of the contract, the submission deadline for the offers is the 5th of the previous month. (Example: start of contract November 1st, 2020; deadline for submitting the offer: October 5th, 2020). Should AOK Nordost award an exclusive contract for the active substance / active substance combination within the framework of an open procedure during the contract period, the contractual regulations concluded in the context of this publication apply. This publication is not a public contract within the meaning of the Coordination Coordination Directive 2014/24 / EU of the European Parliament and of the Council or of public procurement law. In order to ensure the greatest possible degree of transparency for the intended contracts, the publication is published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the procedure name for open procedure, are solely due to the use of this notice form and the publication platform. This does not imply any further significance, in particular submission to public procurement regulations, unless they are required for legal reasons. Since 01.09.2016, the orders placed have only been announced on the website www.aok-gesundheitpartner.de.

The subject of this publication is the conclusion of agreements in accordance with Section 130a (8) SGB V on various active substances / combinations of active substances as part of a so-called open house process. Providing uniform contractual terms and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the conclusion or entry to a discount contract in accordance with Section 130a (8) SGB V for the active substances / combinations of active substances mentioned. Interested pharmaceutical companies can request the participation documents and the contract from the contact address given under l.1). The e-mail address specified under Section I: Contracting authority, point 1.3.) Communication for the purpose of unrestricted and complete fee-free access to the order documents does not exist. Information and the provision of the contract documents can be requested at the following email address: fp_open-house@nordost.aok.de. A precondition for the conclusion of a contract is that the interested pharmaceutical company has completed and signed the requested participation documents. Any pharmaceutical company that meets the participation requirements and documents this by signing the declarations and the discount contract can join the discount contract. There is no exclusivity. The accession or the conclusion of the contract can take place at any time and under the same conditions. Individual contract negotiations are not carried out. The start of the contract can only be one month in advance. The earliest contract start date is October 1st, 2020. Based on this, the contract term is a maximum of 24 months. The contract ends on 30.09.2022 at the latest, regardless of the date of the conclusion of the contract. The offer must be available when the contract begins on October 1, 2020 by August 27, 2020, but no contracts are concluded by AOK Nordost before September 7, 2020. For a later start of the contract, the submission deadline for the offers is the 5th of the previous month. (Example: start of contract November 1st, 2020; deadline for submitting the offer: October 5th, 2020). Should AOK Nordost award an exclusive contract for the active substance / active substance combination within the framework of an open procedure during the contract period, the contractual regulations concluded in the context of this publication apply. This publication is not a public contract within the meaning of the Coordination Coordination Directive 2014/24 / EU of the European Parliament and of the Council or of public procurement law. In order to ensure the greatest possible degree of transparency for the intended contracts, the publication is published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the procedure name for open procedure, are solely due to the use of this notice form and the publication platform. This does not imply any further significance, in particular submission to public procurement regulations, unless they are required for legal reasons. Since 01.09.2016, the orders placed have only been announced on the website www.aok-gesundheitpartner.de.

The subject of this publication is the conclusion of agreements in accordance with Section 130a (8) SGB V on various active substances / combinations of active substances as part of a so-called open house process. Providing uniform contractual terms and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the conclusion or entry to a discount contract in accordance with Section 130a (8) SGB V for the active substances / combinations of active substances mentioned. Interested pharmaceutical companies can request the participation documents and the contract from the contact address given under l.1). The e-mail address specified under Section I: Contracting authority, point 1.3.) Communication for the purpose of unrestricted and complete fee-free access to the order documents does not exist. Information and the provision of the contract documents can be requested at the following email address: fp_open-house@nordost.aok.de. A precondition for the conclusion of a contract is that the interested pharmaceutical company has completed and signed the requested participation documents. Any pharmaceutical company that meets the participation requirements and documents this by signing the declarations and the discount contract can join the discount contract. There is no exclusivity. The accession or the conclusion of the contract can take place at any time and under the same conditions. Individual contract negotiations are not carried out. The start of the contract can only be one month in advance. The earliest contract start date is October 1st, 2020. Based on this, the contract term is a maximum of 24 months. The contract ends on 30.09.2022 at the latest, regardless of the date of the conclusion of the contract. The offer must be available when the contract begins on October 1, 2020 by August 27, 2020, but no contracts are concluded by AOK Nordost before September 7, 2020. For a later start of the contract, the submission deadline for the offers is the 5th of the previous month. (Example: start of contract November 1st, 2020; deadline for submitting the offer: October 5th, 2020). Should AOK Nordost award an exclusive contract for the active substance / active substance combination within the framework of an open procedure during the contract period, the contractual regulations concluded in the context of this publication apply. This publication is not a public contract within the meaning of the Coordination Coordination Directive 2014/24 / EU of the European Parliament and of the Council or of public procurement law. In order to ensure the greatest possible degree of transparency for the intended contracts, the publication is published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the procedure name for open procedure, are solely due to the use of this notice form and the publication platform. This does not imply any further significance, in particular submission to public procurement regulations, unless they are required for legal reasons. Since 01.09.2016, the orders placed have only been announced on the website www.aok-gesundheitpartner.de.

The subject of this publication is the conclusion of agreements in accordance with Section 130a (8) SGB V on various active substances / combinations of active substances as part of a so-called open house process. Providing uniform contractual terms and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the conclusion or entry to a discount contract in accordance with Section 130a (8) SGB V for the active substances / combinations of active substances mentioned. Interested pharmaceutical companies can request the participation documents and the contract from the contact address given under l.1). The e-mail address specified under Section I: Contracting authority, point 1.3.) Communication for the purpose of unrestricted and complete fee-free access to the order documents does not exist. Information and the provision of the contract documents can be requested at the following email address: fp_open-house@nordost.aok.de. A precondition for the conclusion of a contract is that the interested pharmaceutical company has completed and signed the requested participation documents. Any pharmaceutical company that meets the participation requirements and documents this by signing the declarations and the discount contract can join the discount contract. There is no exclusivity. The accession or the conclusion of the contract can take place at any time and under the same conditions. Individual contract negotiations are not carried out. The start of the contract can only be one month in advance. The earliest contract start date is October 1st, 2020. Based on this, the contract term is a maximum of 24 months. The contract ends on 30.09.2022 at the latest, regardless of the date of the conclusion of the contract. The offer must be available when the contract begins on October 1, 2020 by August 27, 2020, but no contracts are concluded by AOK Nordost before September 7, 2020. For a later start of the contract, the submission deadline for the offers is the 5th of the previous month. (Example: start of contract November 1st, 2020; deadline for submitting the offer: October 5th, 2020). Should AOK Nordost award an exclusive contract for the active substance / active substance combination within the framework of an open procedure during the contract period, the contractual regulations concluded in the context of this publication apply. This publication is not a public contract within the meaning of the Coordination Coordination Directive 2014/24 / EU of the European Parliament and of the Council or of public procurement law. In order to ensure the greatest possible degree of transparency for the intended contracts, the publication is published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the procedure name for open procedure, are solely due to the use of this notice form and the publication platform. This does not imply any further significance, in particular submission to public procurement regulations, unless they are required for legal reasons. Since 01.09.2016, the orders placed have only been announced on the website www.aok-gesundheitpartner.de.

The subject of this publication is the conclusion of agreements in accordance with Section 130a (8) SGB V on various active substances / combinations of active substances as part of a so-called open house process. Providing uniform contractual terms and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the conclusion or entry to a discount contract in accordance with Section 130a (8) SGB V for the active substances / combinations of active substances mentioned. Interested pharmaceutical companies can request the participation documents and the contract from the contact address given under l.1). The e-mail address specified under Section I: Contracting authority, point 1.3.) Communication for the purpose of unrestricted and complete fee-free access to the order documents does not exist. Information and the provision of the contract documents can be requested at the following email address: fp_open-house@nordost.aok.de. A precondition for the conclusion of a contract is that the interested pharmaceutical company has completed and signed the requested participation documents. Any pharmaceutical company that meets the participation requirements and documents this by signing the declarations and the discount contract can join the discount contract. There is no exclusivity. The accession or the conclusion of the contract can take place at any time and under the same conditions. Individual contract negotiations are not carried out. The start of the contract can only be one month in advance. The earliest contract start date is October 1st, 2020. Based on this, the contract term is a maximum of 24 months. The contract ends on 30.09.2022 at the latest, regardless of the date of the conclusion of the contract. The offer must be available when the contract begins on October 1, 2020 by August 27, 2020, but no contracts are concluded by AOK Nordost before September 7, 2020. For a later start of the contract, the submission deadline for the offers is the 5th of the previous month. (Example: start of contract November 1st, 2020; deadline for submitting the offer: October 5th, 2020). Should AOK Nordost award an exclusive contract for the active substance / active substance combination within the framework of an open procedure during the contract period, the contractual regulations concluded in the context of this publication apply. This publication is not a public contract within the meaning of the Coordination Coordination Directive 2014/24 / EU of the European Parliament and of the Council or of public procurement law. In order to ensure the greatest possible degree of transparency for the intended contracts, the publication is published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the procedure name for open procedure, are solely due to the use of this notice form and the publication platform. This does not imply any further significance, in particular submission to public procurement regulations, unless they are required for legal reasons. Since 01.09.2016, the orders placed have only been announced on the website www.aok-gesundheitpartner.de.

The subject of this publication is the conclusion of agreements in accordance with Section 130a (8) SGB V on various active substances / combinations of active substances as part of a so-called open house process. Providing uniform contractual terms and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the conclusion or entry to a discount contract in accordance with Section 130a (8) SGB V for the active substances / combinations of active substances mentioned. Interested pharmaceutical companies can request the participation documents and the contract from the contact address given under l.1). The e-mail address specified under Section I: Contracting authority, point 1.3.) Communication for the purpose of unrestricted and complete fee-free access to the order documents does not exist. Information and the provision of the contract documents can be requested at the following email address: fp_open-house@nordost.aok.de. A precondition for the conclusion of a contract is that the interested pharmaceutical company has completed and signed the requested participation documents. Any pharmaceutical company that meets the participation requirements and documents this by signing the declarations and the discount contract can join the discount contract. There is no exclusivity. The accession or the conclusion of the contract can take place at any time and under the same conditions. Individual contract negotiations are not carried out. The start of the contract can only be one month in advance. The earliest contract start date is October 1st, 2020. Based on this, the contract term is a maximum of 24 months. The contract ends on 30.09.2022 at the latest, regardless of the date of the conclusion of the contract. The offer must be available when the contract begins on October 1, 2020 by August 27, 2020, but no contracts are concluded by AOK Nordost before September 7, 2020. For a later start of the contract, the submission deadline for the offers is the 5th of the previous month. (Example: start of contract November 1st, 2020; deadline for submitting the offer: October 5th, 2020). Should AOK Nordost award an exclusive contract for the active substance / active substance combination within the framework of an open procedure during the contract period, the contractual regulations concluded in the context of this publication apply. This publication is not a public contract within the meaning of the Coordination Coordination Directive 2014/24 / EU of the European Parliament and of the Council or of public procurement law. In order to ensure the greatest possible degree of transparency for the intended contracts, the publication is published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the procedure name for open procedure, are solely due to the use of this notice form and the publication platform. This does not imply any further significance, in particular submission to public procurement regulations, unless they are required for legal reasons. Since 01.09.2016, the orders placed have only been announced on the website www.aok-gesundheitpartner.de.

The subject of this publication is the conclusion of agreements in accordance with Section 130a (8) SGB V on various active substances / combinations of active substances as part of a so-called open house process. Providing uniform contractual terms and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the conclusion or entry to a discount contract in accordance with Section 130a (8) SGB V for the active substances / combinations of active substances mentioned. Interested pharmaceutical companies can request the participation documents and the contract from the contact address given under l.1). The e-mail address specified under Section I: Contracting authority, point 1.3.) Communication for the purpose of unrestricted and complete fee-free access to the order documents does not exist. Information and the provision of the contract documents can be requested at the following email address: fp_open-house@nordost.aok.de. A precondition for the conclusion of a contract is that the interested pharmaceutical company has completed and signed the requested participation documents. Any pharmaceutical company that meets the participation requirements and documents this by signing the declarations and the discount contract can join the discount contract. There is no exclusivity. The accession or the conclusion of the contract can take place at any time and under the same conditions. Individual contract negotiations are not carried out. The start of the contract can only be one month in advance. The earliest contract start date is October 1st, 2020. Based on this, the contract term is a maximum of 24 months. The contract ends on 30.09.2022 at the latest, regardless of the date of the conclusion of the contract. The offer must be available when the contract begins on October 1, 2020 by August 27, 2020, but no contracts are concluded by AOK Nordost before September 7, 2020. For a later start of the contract, the submission deadline for the offers is the 5th of the previous month. (Example: start of contract November 1st, 2020; deadline for submitting the offer: October 5th, 2020). Should AOK Nordost award an exclusive contract for the active substance / active substance combination within the framework of an open procedure during the contract period, the contractual regulations concluded in the context of this publication apply. This publication is not a public contract within the meaning of the Coordination Coordination Directive 2014/24 / EU of the European Parliament and of the Council or of public procurement law. In order to ensure the greatest possible degree of transparency for the intended contracts, the publication is published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the procedure name for open procedure, are solely due to the use of this notice form and the publication platform. This does not imply any further significance, in particular submission to public procurement regulations, unless they are required for legal reasons. Since 01.09.2016, the orders placed have only been announced on the website www.aok-gesundheitpartner.de.

The subject of this publication is the conclusion of agreements in accordance with Section 130a (8) SGB V on various active substances / combinations of active substances as part of a so-called open house process. Providing uniform contractual terms and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the conclusion or entry to a discount contract in accordance with Section 130a (8) SGB V for the active substances / combinations of active substances mentioned. Interested pharmaceutical companies can request the participation documents and the contract from the contact address given under l.1). The e-mail address specified under Section I: Contracting authority, point 1.3.) Communication for the purpose of unrestricted and complete fee-free access to the order documents does not exist. Information and the provision of the contract documents can be requested at the following email address: fp_open-house@nordost.aok.de. A precondition for the conclusion of a contract is that the interested pharmaceutical company has completed and signed the requested participation documents. Any pharmaceutical company that meets the participation requirements and documents this by signing the declarations and the discount contract can join the discount contract. There is no exclusivity. The accession or the conclusion of the contract can take place at any time and under the same conditions. Individual contract negotiations are not carried out. The start of the contract can only be one month in advance. The earliest contract start date is October 1st, 2020. Based on this, the contract term is a maximum of 24 months. The contract ends on 30.09.2022 at the latest, regardless of the date of the conclusion of the contract. The offer must be available when the contract begins on October 1, 2020 by August 27, 2020, but no contracts are concluded by AOK Nordost before September 7, 2020. For a later start of the contract, the submission deadline for the offers is the 5th of the previous month. (Example: start of contract November 1st, 2020; deadline for submitting the offer: October 5th, 2020). Should AOK Nordost award an exclusive contract for the active substance / active substance combination within the framework of an open procedure during the contract period, the contractual regulations concluded in the context of this publication apply. This publication is not a public contract within the meaning of the Coordination Coordination Directive 2014/24 / EU of the European Parliament and of the Council or of public procurement law. In order to ensure the greatest possible degree of transparency for the intended contracts, the publication is published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the procedure name for open procedure, are solely due to the use of this notice form and the publication platform. This does not imply any further significance, in particular submission to public procurement regulations, unless they are required for legal reasons. Since 01.09.2016, the orders placed have only been announced on the website www.aok-gesundheitpartner.de.

The subject of this publication is the conclusion of agreements in accordance with Section 130a (8) SGB V on various active substances / combinations of active substances as part of a so-called open house process. Providing uniform contractual terms and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the conclusion or entry to a discount contract in accordance with Section 130a (8) SGB V for the active substances / combinations of active substances mentioned. Interested pharmaceutical companies can request the participation documents and the contract from the contact address given under l.1). The e-mail address specified under Section I: Contracting authority, point 1.3.) Communication for the purpose of unrestricted and complete fee-free access to the order documents does not exist. Information and the provision of the contract documents can be requested at the following email address: fp_open-house@nordost.aok.de. A precondition for the conclusion of a contract is that the interested pharmaceutical company has completed and signed the requested participation documents. Any pharmaceutical company that meets the participation requirements and documents this by signing the declarations and the discount contract can join the discount contract. There is no exclusivity. The accession or the conclusion of the contract can take place at any time and under the same conditions. Individual contract negotiations are not carried out. The start of the contract can only be one month in advance. The earliest contract start date is October 1st, 2020. Based on this, the contract term is a maximum of 24 months. The contract ends on 30.09.2022 at the latest, regardless of the date of the conclusion of the contract. The offer must be available when the contract begins on October 1, 2020 by August 27, 2020, but no contracts are concluded by AOK Nordost before September 7, 2020. For a later start of the contract, the submission deadline for the offers is the 5th of the previous month. (Example: start of contract November 1st, 2020; deadline for submitting the offer: October 5th, 2020). Should AOK Nordost award an exclusive contract for the active substance / active substance combination within the framework of an open procedure during the contract period, the contractual regulations concluded in the context of this publication apply. This publication is not a public contract within the meaning of the Coordination Coordination Directive 2014/24 / EU of the European Parliament and of the Council or of public procurement law. In order to ensure the greatest possible degree of transparency for the intended contracts, the publication is published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the procedure name for open procedure, are solely due to the use of this notice form and the publication platform. This does not imply any further significance, in particular submission to public procurement regulations, unless they are required for legal reasons. Since 01.09.2016, the orders placed have only been announced on the website www.aok-gesundheitpartner.de.

The subject of this publication is the conclusion of agreements in accordance with Section 130a (8) SGB V on various active substances / combinations of active substances as part of a so-called open house process. Providing uniform contractual terms and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the conclusion or entry to a discount contract in accordance with Section 130a (8) SGB V for the active substances / combinations of active substances mentioned. Interested pharmaceutical companies can request the participation documents and the contract from the contact address given under l.1). The e-mail address specified under Section I: Contracting authority, point 1.3.) Communication for the purpose of unrestricted and complete fee-free access to the order documents does not exist. Information and the provision of the contract documents can be requested at the following email address: fp_open-house@nordost.aok.de. A precondition for the conclusion of a contract is that the interested pharmaceutical company has completed and signed the requested participation documents. Any pharmaceutical company that meets the participation requirements and documents this by signing the declarations and the discount contract can join the discount contract. There is no exclusivity. The accession or the conclusion of the contract can take place at any time and under the same conditions. Individual contract negotiations are not carried out. The start of the contract can only be one month in advance. The earliest contract start date is October 1st, 2020. Based on this, the contract term is a maximum of 24 months. The contract ends on 30.09.2022 at the latest, regardless of the date of the conclusion of the contract. The offer must be available when the contract begins on October 1, 2020 by August 27, 2020, but no contracts are concluded by AOK Nordost before September 7, 2020. For a later start of the contract, the submission deadline for the offers is the 5th of the previous month. (Example: start of contract November 1st, 2020; deadline for submitting the offer: October 5th, 2020). Should AOK Nordost award an exclusive contract for the active substance / active substance combination within the framework of an open procedure during the contract period, the contractual regulations concluded in the context of this publication apply. This publication is not a public contract within the meaning of the Coordination Coordination Directive 2014/24 / EU of the European Parliament and of the Council or of public procurement law. In order to ensure the greatest possible degree of transparency for the intended contracts, the publication is published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the procedure name for open procedure, are solely due to the use of this notice form and the publication platform. This does not imply any further significance, in particular submission to public procurement regulations, unless they are required for legal reasons. Since 01.09.2016, the orders placed have only been announced on the website www.aok-gesundheitpartner.de.

The subject of this publication is the conclusion of agreements in accordance with Section 130a (8) SGB V on various active substances / combinations of active substances as part of a so-called open house process. Providing uniform contractual terms and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the conclusion or entry to a discount contract in accordance with Section 130a (8) SGB V for the active substances / combinations of active substances mentioned. Interested pharmaceutical companies can request the participation documents and the contract from the contact address given under l.1). The e-mail address specified under Section I: Contracting authority, point 1.3.) Communication for the purpose of unrestricted and complete fee-free access to the order documents does not exist. Information and the provision of the contract documents can be requested at the following email address: fp_open-house@nordost.aok.de. A precondition for the conclusion of a contract is that the interested pharmaceutical company has completed and signed the requested participation documents. Any pharmaceutical company that meets the participation requirements and documents this by signing the declarations and the discount contract can join the discount contract. There is no exclusivity. The accession or the conclusion of the contract can take place at any time and under the same conditions. Individual contract negotiations are not carried out. The start of the contract can only be one month in advance. The earliest contract start date is October 1st, 2020. Based on this, the contract term is a maximum of 24 months. The contract ends on 30.09.2022 at the latest, regardless of the date of the conclusion of the contract. The offer must be available when the contract begins on October 1, 2020 by August 27, 2020, but no contracts are concluded by AOK Nordost before September 7, 2020. For a later start of the contract, the submission deadline for the offers is the 5th of the previous month. (Example: start of contract November 1st, 2020; deadline for submitting the offer: October 5th, 2020). Should AOK Nordost award an exclusive contract for the active substance / active substance combination within the framework of an open procedure during the contract period, the contractual regulations concluded in the context of this publication apply. This publication is not a public contract within the meaning of the Coordination Coordination Directive 2014/24 / EU of the European Parliament and of the Council or of public procurement law. In order to ensure the greatest possible degree of transparency for the intended contracts, the publication is published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the procedure name for open procedure, are solely due to the use of this notice form and the publication platform. This does not imply any further significance, in particular submission to public procurement regulations, unless they are required for legal reasons. Since 01.09.2016, the orders placed have only been announced on the website www.aok-gesundheitpartner.de.

The subject of this publication is the conclusion of agreements in accordance with Section 130a (8) SGB V on various active substances / combinations of active substances as part of a so-called open house process. Providing uniform contractual terms and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the conclusion or entry to a discount contract in accordance with Section 130a (8) SGB V for the active substances / combinations of active substances mentioned. Interested pharmaceutical companies can request the participation documents and the contract from the contact address given under l.1). The e-mail address specified under Section I: Contracting authority, point 1.3.) Communication for the purpose of unrestricted and complete fee-free access to the order documents does not exist. Information and the provision of the contract documents can be requested at the following email address: fp_open-house@nordost.aok.de. A precondition for the conclusion of a contract is that the interested pharmaceutical company has completed and signed the requested participation documents. Any pharmaceutical company that meets the participation requirements and documents this by signing the declarations and the discount contract can join the discount contract. There is no exclusivity. The accession or the conclusion of the contract can take place at any time and under the same conditions. Individual contract negotiations are not carried out. The start of the contract can only be one month in advance. The earliest contract start date is October 1st, 2020. Based on this, the contract term is a maximum of 24 months. The contract ends on 30.09.2022 at the latest, regardless of the date of the conclusion of the contract. The offer must be available when the contract begins on October 1, 2020 by August 27, 2020, but no contracts are concluded by AOK Nordost before September 7, 2020. For a later start of the contract, the submission deadline for the offers is the 5th of the previous month. (Example: start of contract November 1st, 2020; deadline for submitting the offer: October 5th, 2020). Should AOK Nordost award an exclusive contract for the active substance / active substance combination within the framework of an open procedure during the contract period, the contractual regulations concluded in the context of this publication apply. This publication is not a public contract within the meaning of the Coordination Coordination Directive 2014/24 / EU of the European Parliament and of the Council or of public procurement law. In order to ensure the greatest possible degree of transparency for the intended contracts, the publication is published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the procedure name for open procedure, are solely due to the use of this notice form and the publication platform. This does not imply any further significance, in particular submission to public procurement regulations, unless they are required for legal reasons. Since 01.09.2016, the orders placed have only been announced on the website www.aok-gesundheitpartner.de.